Olafsson B, Forman M B, Puett D W, Pou A, Cates C U, Friesinger G C, Virmani R
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232.
Circulation. 1987 Nov;76(5):1135-45. doi: 10.1161/01.cir.76.5.1135.
We hypothesized that the endogenous coronary vasodilator adenosine may reduce infarct size by progressively increasing reflow in a preparation of coronary occlusion-reperfusion. After 90 min of proximal left anterior descending artery occlusion, 20 dogs were randomized to blood reperfusion with (n = 10) or without (n = 10) adenosine into the proximal left anterior descending vessel at 3.75 mg/min for 60 min after reperfusion. Regional myocardial blood flow was determined serially with microspheres and regional ventricular function was assessed by a computerized radial shortening method. At 24 hr, the area at risk was defined in vivo with monastral blue dye and area of necrosis was determined after incubation of left ventricular slices in triphenyltetrazolium chloride. Hemodynamic variables were similar in the two groups during the experimental protocol. Infarct size was significantly reduced in treated animals, both when expressed as a percentage of the area at risk (9.9 +/- 2.8% vs 40.9 +/- 6.6%, p less than .001) and as a percentage of the left ventricle (4.6 +/- 1.3% vs 18.0 +/- 3.4%, p = .002). This was associated with significant improvement in radial shortening in the ischemic zone 24 hr after reperfusion (10.1 +/- 2.5 vs -2.8 +/- 2.2%, p less than .01). Regional myocardial blood flow was significantly increased in endocardial and epicardial regions from the lateral ischemic zone 1 hr after reperfusion in adenosine-treated animals. Light microscopy demonstrated decreased neutrophil infiltration in the ischemic zone and electron microscopy showed relative preservation of endothelial structure in the subendocardium with reduced neutrophil and red cell stagnation of capillaries in the treated group. These findings suggest that intracoronary administration of adenosine after reperfusion significantly reduces infarct size and improves regional ventricular function in the ischemic zone in the canine preparation.
我们假设内源性冠状动脉血管扩张剂腺苷可能通过在冠状动脉闭塞-再灌注制剂中逐渐增加再灌注来减小梗死面积。在左前降支近端闭塞90分钟后,20只犬被随机分为两组,一组(n = 10)在再灌注后以3.75毫克/分钟的速度向左前降支近端血管内注入腺苷进行血液再灌注60分钟,另一组(n = 10)不注入腺苷。用微球连续测定局部心肌血流量,并通过计算机化的径向缩短法评估局部心室功能。在24小时时,用亚甲蓝染料在体内确定危险区域,并在将左心室切片在氯化三苯基四氮唑中孵育后确定坏死面积。在实验过程中,两组的血流动力学变量相似。治疗组动物的梗死面积显著减小,无论是以危险区域面积的百分比表示(9.9±2.8%对40.9±6.6%,p<0.001),还是以左心室面积的百分比表示(4.6±1.3%对18.0±3.4%,p = 0.002)。这与再灌注后24小时缺血区径向缩短的显著改善相关(10.1±2.5对-2.8±2.2%,p<0.01)。在腺苷治疗的动物中,再灌注1小时后,外侧缺血区的心内膜和心外膜区域的局部心肌血流量显著增加。光镜显示缺血区中性粒细胞浸润减少,电镜显示治疗组心内膜下内皮结构相对保存,毛细血管内中性粒细胞和红细胞淤滞减少。这些发现表明,再灌注后冠状动脉内给予腺苷可显著减小梗死面积,并改善犬制剂中缺血区的局部心室功能。